Antiviral Drugs for EBV
Abstract
:1. Introduction
2. EBV Latency and Antivirals
3. Acyclovir and Infectious Mononucleosis
4. Chronic Active EBV and Post-Transplant Lymphoproliferative Disease (PTLD)
5. Ganciclovir and Valgancyclovir
6. Omaciclovir
7. Valomaciclovir
8. Maribavir
9. Cidofovir
10. Thymidine Derivatives
11. Conclusions
Funding
Conflicts of Interest
References
- Tynell, E.; Aurelius, E.; Brandell, A.; Julander, I.; Wood, M.; Yao, Q.Y.; Rickinson, A.; Akerlund, B.; Andersson, J. Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled study. J. Infect. Dis. 1996, 174, 324–331. [Google Scholar] [CrossRef] [PubMed]
- Pagano, J.S.; Datta, A.K. Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses. Am. J. Med. 1982, 73, 18–26. [Google Scholar] [CrossRef]
- Pagano, J.S.; Sixbey, J.W.; Lin, J.C. Acyclovir and Epstein-Barr virus infection. J. Antimicrob. Chemother. 1983, 12 (Suppl. B), 113–121. [Google Scholar] [CrossRef] [PubMed]
- Colby, B.M.; Shaw, J.E.; Elion, G.B.; Pagano, J.S. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J. Virol. 1980, 34, 560–568. [Google Scholar] [PubMed]
- Adams, A.; Lindahl, T. Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Proc. Natl. Acad. Sci. USA 1975, 72, 1477–1481. [Google Scholar] [CrossRef] [PubMed]
- Gershburg, E.; Pagano, J.S. Epstein-Barr virus infections: Prospects for treatment. J. Antimicrob. Chemother. 2005, 56, 277–281. [Google Scholar] [CrossRef] [PubMed]
- Ernberg, I.; Andersson, J. Acyclovir efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute infectious mononucleosis. J. Gen. Virol. 1986, 67 Pt 10, 2267–2272. [Google Scholar] [CrossRef] [PubMed]
- Drebber, U.; Kasper, H.U.; Krupacz, J.; Haferkamp, K.; Kern, M.A.; Steffen, H.M.; Quasdorff, M.; Zur Hausen, A.; Odenthal, M.; Dienes, H.P. The role of Epstein-Barr virus in acute and chronic hepatitis. J. Hepatol. 2006, 44, 879–885. [Google Scholar] [CrossRef] [PubMed]
- Negro, F. The paradox of Epstein-Barr virus-associated hepatitis. J. Hepatol. 2006, 44, 839–841. [Google Scholar] [CrossRef] [PubMed]
- Sakamoto, Y.; Mariya, Y.; Kubo, K. Quantification of Epstein-Barr virus DNA is helpful for evaluation of chronic active Epstein-Barr virus infection. Tohoku J. Exp. Med. 2012, 227, 307–311. [Google Scholar] [CrossRef] [PubMed]
- Hocker, B.; Bohm, S.; Fickenscher, H.; Kusters, U.; Schnitzler, P.; Pohl, M.; John, U.; Kemper, M.J.; Fehrenbach, H.; Wigger, M.; et al. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl. Int. 2012, 25, 723–731. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malouf, M.A.; Chhajed, P.N.; Hopkins, P.; Plit, M.; Turner, J.; Glanville, A.R. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J. Heart Lung Transplant. 2002, 21, 547–554. [Google Scholar] [CrossRef]
- Hierro, L.; Diez-Dorado, R.; Diaz, C.; De la Vega, A.; Frauca, E.; Camarena, C.; Munoz-Bartolo, G.; Gonzalez de Zarate, A.; Lopez Santamaria, M.; Jara, P. Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus. Liver Transpl. 2008, 14, 1185–1193. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Green, M.; Michaels, M.G. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am. J. Transplant. 2013, 13 (Suppl. 3), 41–54. [Google Scholar] [CrossRef] [PubMed]
- Jones, R.J.; Seaman, W.T.; Feng, W.H.; Barlow, E.; Dickerson, S.; Delecluse, H.J.; Kenney, S.C. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Int. J. Cancer 2007, 121, 1274–1281. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ville, S.; Imbert-Marcille, B.M.; Coste-Burel, M.; Garandeau, C.; Meurette, A.; Cantarovitch, D.; Giral, M.; Hourmant, M.; Blancho, G.; Dantal, J. Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: A retrospective cohort study. Transpl. Int. 2018, 31, 484–494. [Google Scholar] [CrossRef] [PubMed]
- Abele, G.; Eriksson, B.; Harmenberg, J.; Wahren, B. Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrob. Agents Chemother. 1988, 32, 1137–1142. [Google Scholar] [CrossRef] [PubMed]
- Ng, T.I.; Shi, Y.; Huffaker, H.J.; Kati, W.; Liu, Y.; Chen, C.M.; Lin, Z.; Maring, C.; Kohlbrenner, W.E.; Molla, A. Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine. Antimicrob. Agents Chemother. 2001, 45, 1629–1636. [Google Scholar] [CrossRef] [PubMed]
- Biron, K.K.; Harvey, R.J.; Chamberlain, S.C.; Good, S.S.; Smith, A.A., 3rd; Davis, M.G.; Talarico, C.L.; Miller, W.H.; Ferris, R.; Dornsife, R.E.; et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002, 46, 2365–2372. [Google Scholar] [CrossRef] [PubMed]
- Zacny, V.L.; Gershburg, E.; Davis, M.G.; Biron, K.K.; Pagano, J.S. Inhibition of Epstein-Barr virus replication by a benzimidazole l-riboside: Novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl-1H-benzimidazole. J. Virol. 1999, 73, 7271–7277. [Google Scholar] [PubMed]
- Prichard, M.N. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 2009, 19, 215–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chou, S.; Ercolani, R.J.; Sahoo, M.K.; Lefterova, M.I.; Strasfeld, L.M.; Pinsky, B.A. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob. Agents Chemother. 2014, 58, 4697–4702. [Google Scholar] [CrossRef] [PubMed]
- Chou, S.; Bowlin, T.L. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob. Agents Chemother. 2011, 55, 382–384. [Google Scholar] [CrossRef] [PubMed]
- Lurain, N.S.; Chou, S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 2010, 23, 689–712. [Google Scholar] [CrossRef] [PubMed]
- Chou, S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 2008, 18, 233–246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, F.Z.; Roy, D.; Gershburg, E.; Whitehurst, C.B.; Dittmer, D.P.; Pagano, J.S. Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication. J. Virol. 2009, 83, 12108–12117. [Google Scholar] [CrossRef] [PubMed]
- Murata, T.; Isomura, H.; Yamashita, Y.; Toyama, S.; Sato, Y.; Nakayama, S.; Kudoh, A.; Iwahori, S.; Kanda, T.; Tsurumi, T. Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase. Virology 2009, 389, 75–81. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Whitehurst, C.B.; Sanders, M.K.; Law, M.; Wang, F.Z.; Xiong, J.; Dittmer, D.P.; Pagano, J.S. Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. J. Virol. 2013, 87, 5311–5315. [Google Scholar] [CrossRef] [PubMed]
- Snoeck, R.; Andrei, G.; De Clercq, E. Cidofovir in the treatment of HPV-associated lesions. Verh. K. Acad. Geneeskd. Belg. 2001, 63, 93–120. [Google Scholar] [PubMed]
- Yoshizaki, T.; Wakisaka, N.; Kondo, S.; Murono, S.; Shimizu, Y.; Nakashima, M.; Tsuji, A.; Furukawa, M. Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. J. Med. Virol. 2008, 80, 879–882. [Google Scholar] [CrossRef] [PubMed]
- Wakisaka, N.; Yoshizaki, T.; Raab-Traub, N.; Pagano, J.S. Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts. Int. J. Cancer 2005, 116, 640–645. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coen, N.; Singh, U.; Vuyyuru, V.; Van den Oord, J.J.; Balzarini, J.; Duraffour, S.; Snoeck, R.; Cheng, Y.C.; Chu, C.K.; Andrei, G. Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses. J. Virol. 2013, 87, 3839–3851. [Google Scholar] [CrossRef] [PubMed]
- Coen, N.; Duraffour, S.; Haraguchi, K.; Balzarini, J.; van den Oord, J.J.; Snoeck, R.; Andrei, G. Antiherpesvirus activities of two novel 4′-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases. Antimicrob. Agents Chemother. 2014, 58, 4328–4340. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pagano, J.S.; Whitehurst, C.B.; Andrei, G. Antiviral Drugs for EBV. Cancers 2018, 10, 197. https://doi.org/10.3390/cancers10060197
Pagano JS, Whitehurst CB, Andrei G. Antiviral Drugs for EBV. Cancers. 2018; 10(6):197. https://doi.org/10.3390/cancers10060197
Chicago/Turabian StylePagano, Joseph S., Christopher B. Whitehurst, and Graciela Andrei. 2018. "Antiviral Drugs for EBV" Cancers 10, no. 6: 197. https://doi.org/10.3390/cancers10060197